FindTrial
Sign In

Palonosetron for prevention of delayed chemotherapy-induced nausea and vomiting in pediatric patients: a meta-analysis

Palonosetron for prevention of delayed chemotherapy-induced nausea and vomiting in pediatric patients: a meta-analysis - Palonosetron for prevention of delayed chemotherapy-induced nausea and vomiting in pediatric patients: a meta-analysis

Status
Active, not recruiting
Phases
Unknown
Study type
Unknown
Source
JPRN
Registry ID
JPRN-UMIN000050958
Enrollment
Unknown
Registered
2023-05-01
Start date
2023-04-12
Completion date
Unknown
Last updated
2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Chemotherapy-induced nausea and vomiting

Interventions

None listed

Sponsors

Department of Pharmacy, Hokkaido University Hospital
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: We will include randomized controlled trials (RCT) comparing palonosetron with first-generation 5-HT3 receptor antagonists for CINV, evaluating CR in pediatric patients.

Exclusion criteria

Exclusion criteria: Exclude the following 1. Clinical trials comparing different combination regimens including 5-HT3 receptor antagonists and other antiemetics. 2. Incomplete information or data.

Design outcomes

Primary

MeasureTime frame
Complete response (CR: defined as no emesis and no rescue medication) rate for delayed CINV, defined as occurring CINV after 24 hours from chemotherapy, between palonosetron and first-generation 5-HT3 receptor antagonist in pediatric patients.—

Secondary

MeasureTime frame
CR for overall CINV CR for acute CINV, defined as CINV occurring within 24 hours from chemotherapy Incidence of adverse events—

Countries

Japan

Contacts

Public ContactAtsushi Yamaguchi

Hokkaido University Hospital Department of Pharmacy

y-atsushi@huhp.hokudai.ac.jp011-706-5681

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026